Research programme: clindamycin implant - Novalar PharmaceuticalsAlternative Names: Clindamycin-EVA
Latest Information Update: 04 Apr 2014
At a glance
- Originator Harvard School of Dental Medicine; The Forsyth Institute
- Developer Novalar Pharmaceuticals
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Dental infections
Most Recent Events
- 25 Jul 2007 Preclinical trials in Dental infections in USA (Parenteral)